Research Article - Current Pediatric Research (2020) Volume 24, Issue 5

Prevalence and risk factors of severe bacterial infections in thalassemia patients.

Fatma S. Alzhrani^*, Fatima A. Algethmi, Manar A. Makin, Nujud A. Barayan, Rawan M. Hilal, Sarah Matouk Alnakhli

Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

*Corresponding Author:

Fatma S Alzhrani
Faculty of Medicine
King Abdulaziz University
Saudi Arabia
Tel: 0567855009
E-mail: Falzahrani@kau.edu.sa

Accepted on October 01, 2020

Abstract

Background: Thalassemia is an inherited disease, and it is considered as one of the most common monogenic disorders that lead to chronic hemolytic anemia. Thalassemia is newly classified into non–transfusion-dependent thalassemia (NTDT), and transfusion-dependent thalassemia (TDT) based on the necessity of regular blood transfusions. Thalassemia major patients may need a chronic blood transfusion, iron chelation medication, and splenectomy as a part of their treatment. One of the most common causes of death in thalassemia patients is a bacterial infection. The predisposing factors of the infections are either related to the disease itself (e.g. anemia and reticuloendothelial system dysfunction) or to the treatment (e.g. splenectomy, transfusion-related infections, and iron chelation).

Aim: To determine the prevalence and risk factors of severe bacterial infections in NTDT and TDT thalassemia patients at a tertiary hospital

Method: A retrospective study was conducted on patients with NTDT & TDT. Records were scanned from 2014 to 2018 from the hematology department of a tertiary hospital, Jeddah, Saudi Arabia. Patients of all ages who had severe bacterial infection were included in this study.

Results: This study was applied to a total of 231 thalassemia patients at a tertiary hospital in Jeddah, Saudi Arabia. 119 (51.5%) of them were females, and 112 (48.5%) were males; the mean age was 22 years (± SD 13.3). The majority of the patients were TDT 214 (92.6%), and 17 (7.4%) were NTDT. A total of 38 ( 16.5%) thalassemic patients admitted due to bacterial infection. Most of the patients get infected by Escherichia coli, Staphylococcus aureus, and Klebsiella pneumoniae with the percentage of (24.1%, 13.8%, 13.8%), respectively.

Conclusion: In conclusion, Patients undergone splenectomies are not susceptible to bacterial infection. Deferoxamine or iron-chelating drugs does not increase the risk of bacterial infection in patients with thalassemia. Finally, a prophylactic antibiotic is not useful in decreasing bacterial infection in thalassemic patients.

Keywords

Thalasemia, Bacterial infections, Pediatrics

Introduction

Thalassemia is an inherited disease, and it is considered one of the most common monogenic disorders that lead to chronic hemolytic anemia. The pathophysiology of thalassemia in general is imbalance between the α/β-globin [1]. It mainly defects in genes result in diminished synthesis of one or more of the globin subunits [2]. They classified according to the severity of clinical presentation into thalassemia major, thalassemia intermediate, and thalassemia minor [3]. Thalassemia newly classifies into non–transfusion-dependent thalassemia (NTDT), and transfusion-dependent thalassemia (TDT) based on the necessity of regular blood transfusions [4]. The symptoms and severity of thalassemia vary according to how many globins is affected and which type of thalassemia present. From asymptomatic or mild till severe symptoms [5]. Clinical features of the disease develop in the first year of life, Firstly, presents as pallor, accompanied by splenomegaly depend on the severity, fever, and failure to grow [6,7]. High prevalence of the thalassemia was present in the Mediterranean region, Southeast Asia, and Africa population [8].

Thalassemia major patients may need a chronic blood transfusion, iron chelation medication, and splenectomy as a part of their treatment [9]. Transfusion is considered as a primary lifesaver therapy for thalassemia, but it contains significant risk including transfusion reactions, hemosiderosis, infections, and alloimmunization [10]. Hemosiderosis was the commonest complication in chronically transfused patients [11]. One of the most common causes of death in thalassemia patients is a bacterial infection [12-14]. The predisposing factors of the infections are either related to the disease itself (e.g. anemia and reticuloendothelial system dysfunction) or the treatment (e.g. splenectomy, transfusion-related infections, and iron chelation) [15].

There were multiple studies showed that severe complications are still frequent due to iron overload. Regardless of heart failure, infection in patients with thalassemia considered as a common cause of death accounted for 12% to 26% of patient deaths [12,13]. A previous study had estimated that the prevalence of infection ranges from 22.5% to 66% in TM patients [16-19]. Another previous study conducted between (2011-2015) showed that Saudi Arabia has one of the highest prevalence rates of β –thalassemia and Sickle Cell Disease comparing to other countries in the Middle East [20]. Moreover a study conducted in 2015 in Khon Kaen University, Thailand they select 211 thalassemia patients, severe bacterial infections were found in 11 patients of them [3]. Also, there are many risk factors which will make the thalassemia patient more vulnerable to the infection like the duration of the disease, treatment with deferoxamine and if the patient had a splenectomy [15]. Other studies have been done on non-transfusion dependent thalassemia patients (NTDT) to know the prevalence of bacterial infection among them, and the result was moderate. Also, they found that iron overload, deferoxamine therapy, duration after splenectomy for more than ten years considered as a risk factor for severe bacterial infection [3].

Microorganisms such Y. enterocolitica, Klebsiella species, E. coli, Streptococcus pneumonia, P. aeruginosa and Listeria monocytogenes have reported in the state of iron overload [21-23]. Previous studies have found the growth of Klebsiella species as major causative bacteria [3,16,24]. One study in Indonesia showed a significant difference in immune response between Splenectomised and non-splenectomized thalassemia significant patients, and they found that the Splenectomised patients are more susceptible to the infection [24,25]. The most important pathogens in splenectomized are Streptococcus pneumoniae, Haemophilus influenza and Neisseria meningitides [26]. A previous study revealed that splenectomy predisposed thalassemia and sickle cell disease patients to severe infections mostly by Gram-negative microorganisms [19]. In other study, iron overload was a result of regular blood transfusions especially in patients who were not under iron chelating therapy, iron presence lead to more susceptibility of gram-negative bacterial infections in thalassemia patients [27].

However, thalassemia is a common congenital disease, but still, there is no enough data about the risk factors in SA. Also, there are limited recent studies about the prevalence of severe bacterial infection in thalassemia patients. So, we aimed in this study to determine the prevalence and risk factors of severe bacterial infections in NTDT and TDT thalassemia patients. Also, to investigate the spectrum of a causal organisms with thalassemia.

Research Methodology

The study was approved by the unit of biomedical ethics of a tertiary hospital Jeddah, Saudi Arabia. A retrospective study was conducted in 2019. The patient’s records were scanned from 2014 to 2018 from the Hematology Department of a Tertiary Hospital, Jeddah, Saudi Arabia. Transfusion dependent and non-transfusion independent thalassemia patients of all ages who had severe bacterial infection were included in this study. Severe bacterial infection was defined as a bacterial infection necessitating hospitalization. The clinical presentations and laboratory data, including those of potential risk factors for bacterial infection indicated in the literature, were collected. Bacterial infection was confirmed by the isolation of pathogens from blood, pus, stool, cerebrospinal fluid (CSF), and other body fluids. Data entered by excel, and statistical analysis was performed by SPSS 25. Categorical variables, including primary variables, will be described using frequencies. Continuous variables for customarily distributed will be described using mean and Std. The bivariate analysis was conducted for categorical variables using a Chi-square test to check for all the possible risk factors. Experiment with a P-value <0.05 will be considered significant.

Results

In this study, we aimed to determine the prevalence and risk factors of severe bacterial infections in NTDT and TDT thalassemia patients. This study was applied to a total of 231 thalassemia patients at a tertiary hospital in Jeddah, Saudi Arabia. Table 1 shows 119 (51.5%) of them were females and 112 (48.5%) were males; the mean age was 22 years (± SD 13.3), There were 16 different nationalities, the majority were Pakistani patients 71 (30.7%), 66 (28.6%) were Saudi patients, Most of the patients have O+ blood group 91 (39.2%). The majority of the patients were TDT 214 (92.6%), and 17 (7.4) were NTDT, 79.2% of the patients were non-splenectomized, and 20.8% underwent splenectomy, A total of 38 (16.5%) thalassemia patients admitted to a tertiary hospital Jeddah, Saudi Arabia due to bacterial infection, 25 (65.8%) of infected thalassemia patients had positive cultures, Twenty Two (88%) of the infected patients used antibiotics to treat the infection, The mean hospital stay duration for the admitted patients due to infection was 28 days (± SD 42.06) all are summarized in Table 2.

Table 1. Demographic data.

Table 2. Medical history.

The majority of the patients were on TDT 214 (92.6%), 38 (16.5%) admitted to the hospital due infection. 25 (65.8%) had positive culture, 183 (79.2%) were not splenectomise, 22 (88.0%) received antibiotics, 187 (81.0%) were not on prophylaxis. 151 (65.4%)were using defroxaime, 157 (68.0%) were on other chelating drugs, 19 (76.0%) were cured from infection, and only 4 patients (16.0%) had recurrence episode, with mean Hospital stay of 28 days (Table 2).

Most of the patient were infected by Escherichia coli, Staphylococcus aureus and Klebsiella pneumoniae with percentage of (24.1%,13.8%,13.8%) respectively (Table 3).

Table 3. Names of bacteria.

The result revealed a significant association between (TDT, NTDT) and the presence of positive culture (P ≤ 0.036), where the infection was higher among TDT patients. On the other hand, there was no significant association between the presence of positive culture and (splenectomy, prophylaxis, deferoxamine, and other chelating drugs) p-value >0.05 (Tables 4 and 5).

Table 4. The relation between presence of positive and other risk factors.

Table 5. Names of bacterial infection and site of infection.

Discussion

In this retrospective study, we aimed to determine the prevalence and risk factors of severe bacterial infections in NTDT and TDT thalassemia patients at a tertiary hospital in Jeddah, Saudi Arabia. Infections are frequent in thalassemia patients, more than 10% present with severe Infection [15,28-31]. In the present study we reviewed 231 patients (51.5% females, 48.5% males). This study has evaluated that there were Sixty five percent of thalassemic patients had positive blood cultures. In other study by Wang et al, in 2003, recorded 22.5% of TDT had bacterial infection episodes [16].

Regarding our records, the significant organisms infection in TDT were Escherichia coli (24.1%) Staphylococcus aureus (13.8%) and Klebsiella (13.8%). Similarly, In Belgium, they found gram-negative bacteremia by cause of Escherichia coli and Staphylococcus aureus in gram-positive were the most causative agents in hemodialysis patients [32]. In Thailand, in cases of severe infection of β thalassemia, half the causative organisms were gram-negative bacilli such as Escherichia coli and Klebsiella pneumoniae [30]. Both TDT and hemodialysis patients have the same risk of exposure to blood-related infections.

151 of thalassemic patients use deferoxamine as iron chelation therapy, and 13 of them have positive bacterial culture. A study illustrates the effect of deferoxamine treatment on thalassemic patients showed that the infection level raised from 5 to 15 per 100 patients, a patient using deferoxamine are more liable to get infected by Yersinia spp [15,33]. Deferoxamine has a special effect when it comes to Yersinia enterocolitica infection. It interacts with an immune cell that will lead to reducing the immune system, and Yersinia enterocolitica has an outer protein membrane combined with ferrioxamine and release of deferoxamine with free iron [34,35]. There is a possible interaction between the type of iron-chelating therapy and infection based on the literature review.

Microbial agents collaborate with thalassemic hosts when the serum iron levels elevated [33]. Flowing iron overload patients start presented with symptoms (thyroid, hepatic, cardiac and growth disorders) after initiation of chelator therapy, improvement in ferritin level and symptoms was observed, but on the reverse side, the rate of infections raised [15].

This study showed that 68% of thalassemia patients are on iron-chelating therapy other than deferoxamine. However, iron chelating therapy other than deferoxamine did not show a statistically significant association with a bacterial infection. Supporting this, previous studies have found iron-chelating therapy not to enhance the growth of pathogenic organisms in patients with thalassemia [36,37]. Three predisposing factors will elevate the infection rate in thalassemia, the chronicity of the disease, splenectomy, and using deferoxamine as iron chelator therapy [5].

The spleen provides our bodies by important function; it filters our blood as part of the immune system. In this study, we found the relation between the positive culture and splenectomy not significant, which is unexpected. It appears to be different from another study, which indicates that 80% of the patients had S. pneumoniae infection after they underwent to splenectomy by two years and that was before the introduction of the antipneumococcal vaccine, and they indicate that the patients who underwent to splenectomy due to beta-thalassemia have the higher rate of infection than those who had splenectomy for another reason [38]. It shows this result because they divided those children’s who had splenectomy into three groups according to the cause of the splenectomy as if the reason was severe primary disease this by itself will compromise the immunity of the child but if it were due to accidental injury or mild benign condition the risk would below. And there is another study showed that splenectomy increases the susceptibility to the infections especially in younger patients [39]. Other study conducted in Saudi Arabia and they showed that splenectomy could be performed in thalassemic patients over five years of age safely the reason behind this in their research it could be due to the given prophylaxis after the splenectomy on discharge as oral penicillin, 500 mg twice daily throughout the follow-up period. And they also indicate that post-splenectomy septicemia is still considered a significant risk in patients under five years of age [40]. In our study, the patients with Who are not splenectomize they had positive culture more than those who underwent to splenectomy it could be due to the big difference between the numbers of the patients who underwent to splenectomy from those who have not, with that we collected in our sample at a tertiary hospital in Jeddah, Saudi Arabia. Or it could be due to the increased exposure to the blood transfusion in the patient who doesn’t undergo to splenectomy which considers as a risk factor for iron overload, and that will predispose them to the infection.

In 19% of patients receive prophylaxis for infection prevention, this study has documented a non-significant correlation between positive cultured blood specimens and prophylaxis use; only seven patients used prophylaxes and reported positive cultures, while such relation was unavailable in other papers. Post splenectomy sepsis considered to be higher among thalassemia major patients [26]. As the spleen is necessary for the body defense against infection. In the case of spleen absence patients should be protected against the most fearsome organisms (Streptococcus pneumoniae, Haemophilus influenza type B, Neisseria meningitides) [41]. However, immunizations do not fully prevent the infection [42]. But penicillin prophylaxis has been attributed to reducing the incidence of pneumococcal bacteremia by 84%. Both incidence and mortality of postsplenectomy sepsis decreased, by 47% and 88% respectively, with the use of antibiotic prophylaxis [43]. For this reason, it is essential for patients who underwent splenectomy to receive penicillin prophylaxis and vaccinations to reduce the risk of developing sepsis. Furthermore, the mean duration of hospital stay admitted due to infection is 28 days. In the present study, 25 patients with a positive culture for infection, only four patients had a recurrence of the disease.

A limitation of this study is that the relation between iron overload and bacterial infection was not included due to poor documentation of serum ferritin levels. As it is a common disease in our country, we recommend creating a database for thalassemia patients for easier access to information and more accurate results. Researches on a more significant population and different centers need to be done.

Conclusion

In conclusion, patients who undergone splenectomies are not susceptible to bacterial infections. Deferoxamine or ironchelating drugs does not increase the risk of bacterial infection in patients with thalassemia. Finally, a prophylactic antibiotic is not useful in decreasing the bacterial infection in thalassemia. Evaluation for iron excess should be performed regularly in patients with NTDT and TDT. Early recognition of bacterial infection in patients with TDT and NTDT may reduce morbidity and mortality. Further studies should add variables such as serum ferritin level, hemoglobin level, thalassemia face to consider risk factors.

References

1. Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet 2018; 391: 155-67.
2. Kumar V, Abbas A, Fausto N, Aster J, et al. Red blood cell and bleeding disorders. Robbins & Cotran Pathologic Basis of Disease 2010: 629-56.
3. Teawtrakul N, Jetsrisuparb A, Sirijerachai C, et al. Severe bacterial infections in patients with non-transfusion-dependent thalassemia: prevalence and clinical risk factors. Int J Infect Dis 2015; 39: 53-6.
4. Viprakasit V, Ekwattanakit S. Clinical classification, screening and diagnosis for thalassemia. Hematol Oncol Clin North Am 2018; 32: 193-211.
5. Lo L, Singer ST. Thalassemia: Current approach to an old disease. Pediatric Clinics of North America 2002; 49: 1165-91.
6. Borgna C, Galanello R. Thalassemias and related disorders: Quantitative disorders of hemoglobin synthesis. Lancet, 2004.
7. Rebulla P. Blood transfusion in beta thalassaemia major. Transfus Med 1995; 5: 247-58.
8. Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev 2012; 26: S3-6.
9. Biswas A, Firdaus R, Saha K, et al. Post-transfusion hepatitis C virus infection among β-thalassaemic individuals with associated clinical parameters. Indian J Med Res 2018; 147: 581-7.
10. Vichinsky E, Neumayr L, Trimble S, et al. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion 2014; 54: 972-81.
11. Cunningham MJ, Macklin EA, Neufeld EJ, et al. Complications of beta-thalassemia major in North America Blood 2004; 104: 34-9.
12. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989; 2: 27-30.
13. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann NY Acad Sci 2005; 1054: 40-7.
14. Chern JP, Su S, Lin KH, et al. Survival, mortality, and complications in patients with β‐Thalassemia major in Northern Taiwan. Pediatric Blood & Cancer 2007; 48: 550-4.
15. Rahav G, Volach V, Shapiro M, et al. Severe infections in thalassaemic patients: Prevalence and predisposing factors. Br J Haematol 2006; 133: 667-74.
16. Wang SC, Lin KH, Chern JP, et al. Severe bacterial infection in transfusion-dependent patients with thalassemia major. Clin Infect Dis 2003; 37: 984-8.
17. Aswapokee P, Aswapokee N, Fucharoen S, et al. Severe infection in thalassemia: a prospective study. Birth Defects Orig Artic Ser 1987; 23: 521-6.
18. Issaragrisil S, Wanachiwanawin W, Bhuripanyo K, et al. Infection in thalassemia: a retrospective study of 1,018 patients with beta-thalassemia/Hb E disease. Birth Defects Orig Artic Ser 1987; 23: 505-11.
19. Sakran W, Levin C, Kenes Y, et al. Clinical spectrum of serious bacterial infections among splenectomized patients with hemoglobinopathies in Israel: A 37-year follow-up study. Infection. 2012; 40: 35-9.
20. Memish ZA, Saeedi MY. Six-year outcome of the national premarital screening and genetic counseling program for sickle cell disease and β-thalassemia in Saudi Arabia. Ann Saudi Med 2011; 31: 229-35.
21. Bullen J. The significance of iron in infection. Reviews of Infectious Diseases 1981; 3: 1127-38.
22. Miles A, Khimji P, Maskell J. The variable response of bacteria to excess ferric iron in host tissues. Journal of Medical Microbiology. 1979; 12: 17-28.
23. Polk HC, Miles A. Enhancement of bacterial infection by ferric iron: kinetics, mechanisms, and surgical significance. Surgery 1971; 70: 71-7.
24. Yapp AR, Lindeman R, Gilroy N, et al. Infection outcomes in splenectomized patients with hemoglobinopathies in Australia. Int J Infect Dis 2009; 13: 696-700.
25. Sari TT, Gatot D, Akib AA, et al. Immune response of thalassemia major patients in Indonesia with and without splenectomy. Acta Med Indones 2014; 46: 217-25.
26. Bisharat N, Omari H, Lavi I, et al.  Risk of infection and death among post-splenectomy patients. J Infect 2001; 43: 182-6.
27. Suleyman G, Alangaden GJ. Nosocomial Fungal Infections: Epidemiology, Infection Control, and Prevention. Infect Dis Clin North Am 2016; 30: 1023-52.
28. Peng CT, Tsai CH, Wang JH, et al. Bacterial infection in patients with transfusion-dependent beta-thalassemia in central Taiwan. Acta paediatrica Taiwanica= Taiwan er ke yi xue hui za zhi.2000; 41: 318-21.
29. Chung B, Ha S, Chan G, et al. Klebsiella infection in patients with thalassemia. Clinical infectious diseases 2003; 36: 575-9.
30. Wanachiwanawin W. Infections in E-beta thalassemia. J Pediatr Hematol Oncol 2000; 22: 581-7.
31. Li CK, Shing MMK, Chik KW, et al. Klebsiella pneumoniae meningitis in thalassemia major patients. Pediatric Hematology and Oncology 2001;18: 229-32.
32. Tielemans CL, Lenclud CM, Wens R, et al. Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. Nephrology Dialysis Transplantation 1989; 4: 883-7.
33. Vento S, Cainelli F, Cesario F. Infections and thalassaemia. The Lancet Infectious Diseases 2006; 6: 226-33.
34. Báumler AJ, Hantke K. Ferrioxamine uptake in Yersinia enterocolitica: Characterization of the receptor protein FoxA. Molecular Microbiology 1992; 6: 1309-21.
35. Autenrieth IB, Bohn E, Ewald JH, et al. Deferoxamine B but not deferoxamine G1 inhibits cytokine production in murine bone marrow macrophages. Journal of Infectious Diseases 1995; 172: 490-6.
36. Chan GC, Chan S, Ho PL, et al. Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. Hemoglobin 2009; 33: 352-60.
37. Lesic B, Foulon J, Carniel E. Comparison of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica. Antimicrob Agents Chemother 2002; 46: 1741-5.
38. Eraklis AJ, Kevy SV, Diamond LK, et al. Hazard of overwhelming infection after splenectomy in childhood. N Engl J Med 1967; 276: 1225-9.
39. Eraklis AJ, Filler RM. Splenectomy in childhood: A review of 1413 cases. J Pediatr Surg 1972; 7:382-8.
40. Al-Hawsawi ZM, Hummaida TI, Ismail GA. Splenectomy in thalassaemia major: experience at Madina Maternity and Children's Hospital, Saudi Arabia. Ann Trop Paediatr 2001; 21: 155-8.
41. Sumaraju V, Smith LG, Smith SM. Infectious complications in asplenic hosts. Infect Dis Clin North Am 2001; 15: 551-65.
42. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000; 106: 362-6.
43. Jugenburg M, Haddock G, Freedman MH, et al. The morbidity and mortality of pediatric splenectomy: does prophylaxis make a difference? J Pediatr Surg 1999; 34: 1064-7.